Maintaining MOMENTUM in myelofibrosis

Affiliations

¹ Department of Medicine, Division of Hematology Oncology and Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
² Department of Medicine, Division of Hematology Oncology and Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. Electronic address: bridget.marcellino@mssm.edu.

Comment

Marina Kremyanskaya et al. Lancet Haematol. 2023 Sep.

. 2023 Sep;10(9):e697-e699.

doi: 10.1016/S2352-3026(23)00208-9. Epub 2023 Jul 27.

¹ Department of Medicine, Division of Hematology Oncology and Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
² Department of Medicine, Division of Hematology Oncology and Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. Electronic address: bridget.marcellino@mssm.edu.

No abstract available

Comment on

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study.
Gerds AT, Verstovsek S, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, Grosicki S, Iurlo A, Goh YT, Lazaroiu MC, Egyed M, Fox ML, McLornan D, Perkins A, Yoon SS, Gupta V, Kiladjian JJ, Granacher N, Lee SE, Ocroteala L, Passamonti F, Harrison CN, Oh S, Klencke BJ, Yu J, Donahue R, Kawashima J, Mesa R. Gerds AT, et al. Lancet Haematol. 2023 Sep;10(9):e735-e746. doi: 10.1016/S2352-3026(23)00174-6. Epub 2023 Jul 27. Lancet Haematol. 2023. PMID: 37517413 Clinical Trial.